These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25034357)

  • 1. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy.
    Di Matteo M; Samara-Kuko E; Ward NJ; Waddington SN; McVey JH; Chuah MK; VandenDriessche T
    Mol Ther; 2014 Sep; 22(9):1614-24. PubMed ID: 25034357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.
    Nair N; Rincon MY; Evens H; Sarcar S; Dastidar S; Samara-Kuko E; Ghandeharian O; Man Viecelli H; Thöny B; De Bleser P; VandenDriessche T; Chuah MK
    Blood; 2014 May; 123(20):3195-9. PubMed ID: 24637359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
    Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
    Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.
    Suwanmanee T; Hu G; Gui T; Bartholomae CC; Kutschera I; von Kalle C; Schmidt M; Monahan PE; Kafri T
    Mol Ther; 2014 Mar; 22(3):567-574. PubMed ID: 23941813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo.
    Mikkelsen JG; Yant SR; Meuse L; Huang Z; Xu H; Kay MA
    Mol Ther; 2003 Oct; 8(4):654-65. PubMed ID: 14529839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
    Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
    Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable transduction of the neonatal mouse liver using a hybrid rAAV/sleeping beauty transposon gene delivery system.
    Cunningham SC; Zakas PM; Sasaki N; van Dijk EB; Zhu E; Fu Y; Salomon WE; Citorik RJ; Rubens JR; Cotta-Ramusino C; Querbes W; Alexander IE
    J Gene Med; 2024 Aug; 26(8):e3726. PubMed ID: 39160647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.
    Hausl MA; Zhang W; Müther N; Rauschhuber C; Franck HG; Merricks EP; Nichols TC; Kay MA; Ehrhardt A
    Mol Ther; 2010 Nov; 18(11):1896-906. PubMed ID: 20717103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
    Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
    Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
    Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals.
    Hausl M; Zhang W; Voigtländer R; Müther N; Rauschhuber C; Ehrhardt A
    Curr Gene Ther; 2011 Oct; 11(5):363-74. PubMed ID: 21888620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactive piggyBac gene transfer in human cells and in vivo.
    Doherty JE; Huye LE; Yusa K; Zhou L; Craig NL; Wilson MH
    Hum Gene Ther; 2012 Mar; 23(3):311-20. PubMed ID: 21992617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A David promoter with Goliath strength.
    Markusic DM; Herzog RW
    Blood; 2014 May; 123(20):3068-9. PubMed ID: 24832942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transposons: Moving Forward from Preclinical Studies to Clinical Trials.
    Tipanee J; VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1087-1104. PubMed ID: 28920716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.